• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌:流行病学和危险因素。

Cholangiocarcinoma: Epidemiology and risk factors.

机构信息

Department of Hepatology, St Mary's Hospital, Imperial College London, London, United Kingdom.

Center of Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy.

出版信息

Liver Int. 2019 May;39 Suppl 1:19-31. doi: 10.1111/liv.14095. Epub 2019 Mar 24.

DOI:10.1111/liv.14095
PMID:30851228
Abstract

Cholangiocarcinoma (CCA) is a heterogeneous disease arising from a complex interaction between host-specific genetic background and multiple risk factors. Globally, CCA incidence rates exhibit geographical variation, with much higher incidence in parts of the Eastern world compared to the West. These differences are likely to reflect differences in geographical risk factors as well as genetic determinants. Of note, over the past few decades, the incidence rates of CCA appear to change and subtypes of CCA appear to show distinct epidemiological trends. These trends need to be interpreted with caution given the issues of diagnosis, recording and coding of subtypes of CCA. Epidemiological evidences suggest that in general population some risk factors are less frequent but associated with a higher CCA risk, while others are more common but associated with a lower risk. Moreover, while some risk factors are shared by intrahepatic and both extrahepatic forms, others seem more specific for one of the two forms. Currently some pathological conditions have been clearly associated with CCA development, and other conditions are emerging; however, while their impact in increasing CCA risk as single etiological factors has been provided in many studies, less is known when two or more risk factors co-occur in the same patient. Moreover, despite the advancements in the knowledge of CCA aetiology, in Western countries about 50% of cases are still diagnosed without any identifiable risk factor. It is therefore conceivable that other still undefined etiologic factors are responsible for the recent increase of CCA (especially iCCA) incidence worldwide.

摘要

胆管癌(CCA)是一种异质性疾病,由宿主特异性遗传背景与多种风险因素之间的复杂相互作用引起。在全球范围内,CCA 的发病率存在地域差异,与西方相比,东方世界的发病率更高。这些差异可能反映了地域风险因素以及遗传决定因素的差异。值得注意的是,在过去几十年中,CCA 的发病率似乎发生了变化,并且 CCA 的亚型似乎表现出明显的流行病学趋势。鉴于 CCA 亚型的诊断、记录和编码问题,需要谨慎解释这些趋势。流行病学证据表明,在一般人群中,一些风险因素不太常见但与更高的 CCA 风险相关,而另一些则更为常见但与更低的风险相关。此外,虽然一些风险因素与肝内和肝外两种形式都有关,但其他因素似乎更特定于其中一种形式。目前,一些病理状况已明确与 CCA 的发生有关,其他状况也在不断涌现;然而,虽然在许多研究中已经提供了这些风险因素作为单一病因因素对增加 CCA 风险的影响,但当两个或更多风险因素同时存在于同一患者中时,其影响知之甚少。此外,尽管对 CCA 病因学的认识有所提高,但在西方国家,仍有约 50%的病例没有任何可识别的风险因素。因此,可以想象,其他尚未明确的病因因素可能是导致全球范围内 CCA(尤其是 iCCA)发病率最近增加的原因。

相似文献

1
Cholangiocarcinoma: Epidemiology and risk factors.胆管癌:流行病学和危险因素。
Liver Int. 2019 May;39 Suppl 1:19-31. doi: 10.1111/liv.14095. Epub 2019 Mar 24.
2
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.肝内和肝外胆管癌的危险因素:系统评价和荟萃分析。
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
3
Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.德国胆管癌:流行病学趋势和分类错误的影响。
Liver Int. 2019 Feb;39(2):316-323. doi: 10.1111/liv.13954. Epub 2018 Oct 8.
4
Epidemiology of cholangiocarcinoma.胆管癌的流行病学
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32. doi: 10.1016/j.bpg.2015.02.003. Epub 2015 Feb 16.
5
Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia.肝内胆管癌和肝外胆管癌发病率的比较——聚焦于东亚和东南亚地区。
Asian Pac J Cancer Prev. 2010;11(5):1159-66.
6
Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma: Association of diabetes mellitus and cholangiocarcinoma.糖尿病:胆管癌的潜在风险及促发因素:糖尿病与胆管癌的关联
Cancer Epidemiol. 2015 Jun;39(3):274-8. doi: 10.1016/j.canep.2015.04.002. Epub 2015 Apr 22.
7
Clinical presentation, risk factors and staging systems of cholangiocarcinoma.胆管癌的临床表现、危险因素及分期系统
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):245-52. doi: 10.1016/j.bpg.2015.02.001. Epub 2015 Feb 14.
8
Cholangiocarcinoma miscoding in hepatobiliary centres.肝胆中心胆管癌错配。
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
9
Epidemiological aspects of biliary tree tumors in a region of northern Italy: emerging trends and sex-based differences.意大利北部地区胆道系统肿瘤的流行病学特征:新兴趋势和性别差异。
Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1347-51. doi: 10.1097/MEG.0b013e3283636cfb.
10
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.美国 2001 至 2017 年胆管癌发病率和死亡率的时间变化。
Oncologist. 2022 Oct 1;27(10):874-883. doi: 10.1093/oncolo/oyac150.

引用本文的文献

1
Advances in Endoscopic Diagnosis and Management of Cholangiocarcinoma.胆管癌的内镜诊断与治疗进展
J Clin Med. 2025 Aug 26;14(17):6028. doi: 10.3390/jcm14176028.
2
Genomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut-Liver Axis in Tumorigenesis and Therapy.肝癌中的基因组改变与微生物群串扰:肿瘤发生与治疗中的肠-肝轴
Genes (Basel). 2025 Jul 30;16(8):920. doi: 10.3390/genes16080920.
3
Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.
超声造影诊断肝内胆管癌亚型:与低分化肝细胞癌的对比研究
Cancer Imaging. 2025 Aug 27;25(1):107. doi: 10.1186/s40644-025-00923-8.
4
Safety profiles of the new target therapies-pemigatinib, futibatinib, and ivosidenib-for the treatment of cholangiocarcinoma: a systematic review.用于治疗胆管癌的新型靶向疗法(培米替尼、呋喹替尼和艾伏尼布)的安全性概况:一项系统评价
Ther Adv Drug Saf. 2025 Aug 19;16:20420986251347376. doi: 10.1177/20420986251347376. eCollection 2025.
5
Gallbladder and biliary tract cancer burden trends in Brazil, Russian Federation, India, China, and South Africa in 1990-2021.1990 - 2021年巴西、俄罗斯联邦、印度、中国和南非的胆囊及胆道癌负担趋势
World J Gastrointest Oncol. 2025 Aug 15;17(8):109245. doi: 10.4251/wjgo.v17.i8.109245.
6
ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma.ZEB1对肝细胞癌中索拉非尼和Mdivi-1联合治疗的反应进行分层。
Sci Rep. 2025 Aug 19;15(1):30451. doi: 10.1038/s41598-025-16379-6.
7
Establishment and characterization of a new Chinese extrahepatic cholangiocarcinoma cell line, EBC-X1.一种新的中国肝外胆管癌细胞系EBC-X1的建立与鉴定。
Hum Cell. 2025 Aug 17;38(5):144. doi: 10.1007/s13577-025-01276-x.
8
Role of interleukins in the pathogenesis of cholangiocarcinoma: A literature review.白细胞介素在胆管癌发病机制中的作用:文献综述。
World J Gastrointest Oncol. 2025 Jul 15;17(7):107341. doi: 10.4251/wjgo.v17.i7.107341.
9
Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.不可切除胆管癌的靶向治疗和免疫治疗
Chin Med J (Engl). 2025 Aug 20;138(16):1904-1926. doi: 10.1097/CM9.0000000000003705. Epub 2025 Jul 21.
10
Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives.胆管癌中的循环肿瘤DNA:当前临床应用及未来展望
Front Cell Dev Biol. 2025 Jul 2;13:1616064. doi: 10.3389/fcell.2025.1616064. eCollection 2025.